Prevalence of Decisional Regret and Associated Risk Factors in Patients With Hepatitis B Undergoing Pegylated Interferon Alpha Therapy
- 1Department of Gastroenterology The National Key Clinical Specialty Zhongshan Hospital of Xiamen University School of Medicine Xiamen University Xiamen Fujian Province China xmu.edu.cn
- 2Clinical Research Center for Gut Microbiota and Digestive Diseases of Fujian Province Xiamen Key Laboratory of Intestinal Microbiome and Human Health Xiamen Fujian Province China
- 3Department of Digestive Disease Institute for Microbial Ecology School of Medicine Xiamen University Xiamen Fujian Province China xmu.edu.cn
Abstract
Background: Pegylated interferon alpha has been shown to enhance the likelihood of achieving a functional cure in patients with hepatitis B. However, it was associated with a greater number of contraindications and adverse reactions compared with nucleotide analogs. Current research has placed comparatively less emphasis on the potential for this treatment to induce decision regret among patients.
Aim:: The aim of this study was to investigate the current status of decision regret in hepatitis B patients undergoing interferon therapy and to explore its influencing factors.
Method: A cross‐sectional study was conducted in a comprehensive hospital in Xiamen, Fujian Province, China, from February 20 to June 13, 2024. The study recruited hepatitis B patients undergoing treatment with pegylated interferon alpha. The survey encompassed general information, the All Aspects of Health Literacy Scale, the Perceived Social Support Scale, the Control Preferences Scale, the Decisional Conflict Scale, and the Decision Regret Scale.
Results: A total of 130 questionnaires were analyzed. Only 13.85% of patients had no regrets at all about the decision, 34.60% experienced mild regret, and the proportion of patients with moderate to severe regrets reached 51.50%. Mild impact on life, active decision‐making roles, passive decision‐making roles, and decision conflict were the influencing factors of decisional regret in hepatitis B patients on pegylated interferon alpha therapy, which together explained 29.6% of the total variation.
Conclusion: Hepatitis B patients undergoing pegylated interferon alpha therapy had a high percentage of decisional regret. Healthcare professionals should pay close attention to this phenomenon. In the future, they can investigate additional potential influencing factors and promptly develop intervention strategies to effectively reduce decision regret.
Related
- Prevalence and factors associated with hepatitis B surface antibody seroprotection among healthcare workers undergoing laboratory testing at Eastgate Clinic, Windhoek, Namibia: A retrospective cross-sectional study
- Prevalence and factors associated with pulmonary hypertension in patients undergoing maintenance hemodialysis: a systematic review and meta-analysis
- Echocardiographic Left Ventricular Hypertrophy Among Patients with Type 2 Diabetes Undergoing Clinically Indicated Echocardiography at a Saudi Cardiac Center: Prevalence and Associated Factors
- Hepatitis E Virus Prevalence and Associated Risk Factors in Pregnant Women Attending Antenatal Consultations Niger Republic, 2025
- Prevalence of Y93H resistance-associated substitution in treatment-naïve hepatitis C virus genotype 1b patients: a systematic review and meta-analysis.
BibTeX
@article{lin2026prevalence,
title = {{Prevalence of Decisional Regret and Associated Risk Factors in Patients With Hepatitis B Undergoing Pegylated Interferon Alpha Therapy}},
author = {Yufen Lin and Huan Xiong and Shuanglian Yi and Shanshan Xie},
journal = {Gastroenterology Research and Practice},
year = {2026},
month = oct,
doi = {10.1155/grp/5837940},
url = {https://doi.org/10.1155/grp/5837940},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prevalence of Decisional Regret and Associated Risk Factors in Patients With Hepatitis B Undergoing Pegylated Interferon Alpha Therapy
AU - Yufen Lin
AU - Huan Xiong
AU - Shuanglian Yi
AU - Shanshan Xie
PY - 2026
DA - 2026/10/26
JO - Gastroenterology Research and Practice
DO - 10.1155/grp/5837940
UR - https://doi.org/10.1155/grp/5837940
AB - Background: Pegylated interferon alpha has been shown to enhance the likelihood of achieving a functional cure in patients with hepatitis B. However, it was associated with a greater number of contraindications and adverse reactions compared with nucleotide analogs. Current research has placed comparatively less emphasis on the potential for this treatment to induce decision regret among patients. Aim:: The aim of this study was to investigate the current status of decision regret in hepatitis B patients undergoing interferon therapy and to explore its influencing factors. Method: A cross‐sectional study was conducted in a comprehensive hospital in Xiamen, Fujian Province, China, from February 20 to June 13, 2024. The study recruited hepatitis B patients undergoing treatment with pegylated interferon alpha. The survey encompassed general information, the All Aspects of Health Literacy Scale, the Perceived Social Support Scale, the Control Preferences Scale, the Decisional Conflict Scale, and the Decision Regret Scale. Results: A total of 130 questionnaires were analyzed. Only 13.85% of patients had no regrets at all about the decision, 34.60% experienced mild regret, and the proportion of patients with moderate to severe regrets reached 51.50%. Mild impact on life, active decision‐making roles, passive decision‐making roles, and decision conflict were the influencing factors of decisional regret in hepatitis B patients on pegylated interferon alpha therapy, which together explained 29.6% of the total variation. Conclusion: Hepatitis B patients undergoing pegylated interferon alpha therapy had a high percentage of decisional regret. Healthcare professionals should pay close attention to this phenomenon. In the future, they can investigate additional potential influencing factors and promptly develop intervention strategies to effectively reduce decision regret.
SN - 1687-6121
SN - 1687-630X
ER -